3.80
price down icon3.06%   -0.12
after-market Handel nachbörslich: 3.76 -0.04 -1.05%
loading
Schlusskurs vom Vortag:
$3.92
Offen:
$3.92
24-Stunden-Volumen:
16,534
Relative Volume:
0.11
Marktkapitalisierung:
$15.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.67M
KGV:
-1.2298
EPS:
-3.09
Netto-Cashflow:
$-101.06M
1W Leistung:
-8.21%
1M Leistung:
+897.38%
6M Leistung:
+1,488%
1J Leistung:
+804.55%
1-Tages-Spanne:
Value
$3.80
$4.04
1-Wochen-Bereich:
Value
$3.80
$4.59
52-Wochen-Spanne:
Value
$0.2195
$4.59

Athira Pharma Inc Stock (ATHA) Company Profile

Name
Firmenname
Athira Pharma Inc
Name
Telefon
(425) 620-8501
Name
Adresse
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Name
Mitarbeiter
26
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-07
Name
Neueste SEC-Einreichungen
Name
ATHA's Discussions on Twitter

Vergleichen Sie ATHA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ATHA
Athira Pharma Inc
3.80 15.46M 0 -117.67M -101.06M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.79 106.37B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.46 59.90B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.63 60.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
796.92 49.56B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.10 36.88B 4.56B -176.77M 225.30M -1.7177

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-09-19 Herabstufung Mizuho Outperform → Neutral
2024-09-04 Herabstufung BTIG Research Buy → Neutral
2024-09-04 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2024-09-04 Herabstufung Rodman & Renshaw Buy → Neutral
2024-08-19 Eingeleitet Rodman & Renshaw Buy
2022-10-17 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2022-07-07 Eingeleitet Mizuho Buy
2022-06-23 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2022-06-23 Herabstufung Jefferies Buy → Hold
2022-06-23 Herabstufung Stifel Buy → Hold
2022-05-10 Eingeleitet BTIG Research Buy
2022-04-21 Eingeleitet Berenberg Buy
2021-12-15 Eingeleitet Goldman Neutral
2020-10-13 Eingeleitet Goldman Buy
2020-10-13 Eingeleitet JMP Securities Mkt Outperform
2020-10-13 Eingeleitet Jefferies Buy
2020-10-13 Eingeleitet Stifel Buy
Alle ansehen

Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten

pulisher
Oct 10, 2025

Key metrics from Athira Pharma Inc.’s quarterly data2025 Market Overview & Free Real-Time Volume Trigger Notifications - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Analyzing recovery setups for Athira Pharma Inc. investors2025 Stock Rankings & Weekly Watchlist of Top Performers - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Will Athira Pharma Inc. stock sustain high P E ratiosJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

What recovery options are there for Athira Pharma Inc.2025 Top Gainers & Technical Pattern Alert System - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Real time scanner hits for Athira Pharma Inc. explainedJuly 2025 Analyst Calls & High Accuracy Trade Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Measuring Athira Pharma Inc.’s beta against major indicesWeekly Investment Recap & Smart Swing Trading Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is Athira Pharma Inc. forming a bottoming baseJuly 2025 Recap & Safe Capital Growth Stock Tips - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is it time to cut losses on Athira Pharma Inc.2025 Dividend Review & Reliable Breakout Stock Forecasts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is Athira Pharma Inc. still worth holding after the dipChart Signals & High Win Rate Trade Tips - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

News impact scoring models applied to Athira Pharma Inc.Weekly Trade Report & Real-Time Buy Zone Alerts - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Quantitative breakdown of Athira Pharma Inc. recent moveJuly 2025 Reactions & Community Supported Trade Ideas - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Multi factor analysis applied to Athira Pharma Inc.July 2025 News Drivers & Accurate Entry and Exit Point Alerts - newser.com

Oct 09, 2025
pulisher
Oct 06, 2025

Will Athira Pharma Inc. price bounce be sustainableWeekly Investment Recap & Reliable Breakout Forecasts - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

What institutional flow reveals about Athira Pharma Inc.Rate Cut & Low Risk Growth Stock Ideas - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Regression analysis insights on Athira Pharma Inc. performance2025 Analyst Calls & AI Enhanced Execution Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Full technical analysis of Athira Pharma Inc. stockWatch List & Free Expert Verified Stock Movement Alerts - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Athira Pharma regains Nasdaq compliance after meeting minimum bid requirement - Investing.com

Oct 03, 2025
pulisher
Oct 03, 2025

Building trade automation scripts for Athira Pharma Inc.July 2025 Review & Risk Controlled Swing Trade Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Will Athira Pharma Inc. see short term momentumEarnings Overview Summary & AI Driven Stock Movement Reports - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Published on: 2025-10-02 23:40:16 - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Published on: 2025-10-02 21:18:52 - newser.com

Oct 02, 2025

Finanzdaten der Athira Pharma Inc-Aktie (ATHA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Athira Pharma Inc-Aktie (ATHA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
Jul 01 '25
Sale
0.29
8,526
2,502
168,901
Litton Mark James
President and CEO
Jun 30 '25
Option Exercise
0.00
108,334
0
350,925
Litton Mark James
President and CEO
Jul 01 '25
Sale
0.29
25,123
7,374
325,802
San Martin Javier
CHIEF MEDICAL OFFICER
Jun 30 '25
Option Exercise
0.00
46,666
0
82,507
San Martin Javier
CHIEF MEDICAL OFFICER
Jul 01 '25
Sale
0.29
10,842
3,182
71,665
Worthington Mark
General Counsel and CCO
Jun 30 '25
Option Exercise
0.00
36,666
0
120,401
Worthington Mark
General Counsel and CCO
Jul 01 '25
Sale
0.29
8,526
2,502
111,875
Renninger Robert
SVP, Finance and Accounting
Jun 30 '25
Option Exercise
0.00
12,359
0
112,083
Renninger Robert
SVP, Finance and Accounting
Jul 01 '25
Sale
0.29
2,897
850
109,186
$21.35
price down icon 5.74%
$83.80
price down icon 1.12%
$31.81
price down icon 0.13%
$102.06
price down icon 2.32%
$162.33
price down icon 1.26%
biotechnology ONC
$320.10
price down icon 4.68%
Kapitalisierung:     |  Volumen (24h):